Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy

Hematology/Oncology Clinics of North America

Volumn 31, Issue 5, 2017, Pages 721-735

  Kohn, Donald B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gammaretroviral vector; Gene editing; Gene therapy; Hematopoietic stem cells; Homologous recombination; Lentiviral vector; Site specific endonucleases

Indexed keywords

FLUDARABINE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ADA GENE; ADRENOLEUKODYSTROPHY; ALDP GENE; ASA GENE; BETA THALASSEMIA; CELLULAR IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; CLINICAL EFFECTIVENESS; GENE; GENE EDITING; HBG GENE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IL2RG GENE; IMMUNE RESPONSE; INDUCED PLURIPOTENT STEM CELL; METACHROMATIC LEUKODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SICKLE CELL ANEMIA; STEM CELL GENE THERAPY; WASP GENE; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ADVERSE EFFECTS; ANIMAL; CLINICAL TRIAL (TOPIC); CYTOLOGY; GAMMARETROVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HEMATOPOIETIC STEM CELL; HISTORY; HOMOLOGOUS RECOMBINATION; LENTIVIRINAE; METABOLISM; PROCEDURES; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; GAMMARETROVIRUS; GENE EDITING; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HOMOLOGOUS RECOMBINATION; HUMANS; LENTIVIRUS;

EID: 85029306016     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2017.06.006     Document Type: Review

References (82)

1. Friedmann, T., Roblin, R., Gene therapy for human genetic disease?. Science 175:4025 (1972), 949–955.
2. Anderson, W.F., Fletcher, J.C., Sounding boards. Gene therapy in human beings: when is it ethical to begin?. N Engl J Med 303:22 (1980), 1293–1297.
3. Williamson, B., Reintroduction of genetically transformed bone marrow cells into mice. Nature 284:5755 (1980), 397–398.
4. Mercola, K.E., Stang, H.D., Browne, J., et al. Insertion of a new gene of viral origin into bone marrow cells of mice. Science 208:4447 (1980), 1033–1035.
5. Jacobs, P., the Los Angeles Times, Doctor tried gene therapy on 2 humans. The Washington Post, 1980.
6. Schmeck, H.M. Jr., U.S. agency disciplines gene-splicing researcher. New York Times, 1981.
7. Wivel, N.A., Historical perspectives pertaining to the NIH Recombinant DNA Advisory Committee. Hum Gene Ther 25:1 (2014), 19–24.
8. Fredrickson, D.S., Asilomar and recombinant DNA: the end of the beginning. Institute of Medicine (US) Committee to Study Decision Making, Hanna, K.E., (eds.) Biomedical Politics, 1991, National Academies Press (US), Washington (DC), 258–308 Available at: https://www.ncbi.nlm.nih.gov/books/NBK234217/?report=classic.
9. Cone, R.D., Mulligan, R.C., High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci U S A 81 (1984), 6349–6353.
10. Armentano, D., Yu, S.F., Kantoff, P.W., et al. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 230 (1985), 1395–1398.
11. Williams, D.A., Lemischka, I.R., Nathan, D.G., et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310 (1984), 476–480.
12. Eglitis, M.A., Kantoff, P., Gilboa, E., et al. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 230 (1985), 1395–1398.
13. Dick, J.E., Magli, M.C., Huszar, D., et al. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42:1 (1985), 71–79.
14. Belmont, J.W., Henkel-Tigges, J., Chang, S.M., et al. Expression of human adenosine deaminase in murine haematopoietic progenitor cells following retroviral transfer. Nature 322 (1986), 385–387.
15. Karlsson, S., Bodine, D.M., Perry, L., et al. Expression of the human beta-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice. Proc Natl Acad Sci U S A 85:16 (1988), 6062–6066.
16. Gruber, H.E., Finley, K.D., Hershberg, R.M., et al. Retroviral vector-mediated gene transfer into human hematopoietic progenitor cells. Science 230 (1985), 1057–1061.
17. Schuening, F.G., Kawahara, K., Miller, A.D., et al. Retrovirus-mediated gene transduction into long-term repopulating marrow cells of dogs. Blood 78 (1991), 2568–2576.
18. Miller, A.D., Buttimore, C., Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6 (1986), 2895–2902.
19. Markowitz, D., Goff, S., Bank, A., A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62 (1988), 1120–1124.
20. Donahue, R.E., Kessler, S.W., Bodine, D., et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 176 (1992), 1125–1135.
21. Bordignon, C., Notarangelo, L.D., Nobili, N., et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270:5235 (1995), 470–475.
22. Kohn, D.B., Weinberg, K.I., Nolta, J.A., et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1:10 (1995), 1017–1023.
23. Dunbar, C.E., Kohn, D.B., Schiffmann, R., et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 9:17 (1998), 2629–2640.
24. Malech, H.L., Maples, P.B., Whiting-Theobald, N., et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 94:22 (1997), 12133–12138.
25. Bauer, T.R., Schwartz, B.R., Liles, W.C., et al. Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34+ cells derived from a patient with leukocyte adhesion deficiency type 1. Blood 91:5 (1998), 1520–1526.
26. Schmidt, M., Carbonaro, D.A., Speckmann, C., et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med 9:4 (2003), 463–468.
27. Miller, A.D., Garcia, J.V., von Suhr, N., et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 65:5 (1991), 2220–2224.
28. Moritz, T., Patel, V.P., Williams, D.A., Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin Invest 93:4 (1994), 1451–1457.
29. Pollok, K.E., Hanenberg, H., Noblitt, T.W., et al. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol 72:6 (1998), 4882–4892.
30. Dao, M.A., Hashino, K., Kato, I., et al. Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 92:12 (1998), 4612–4621.
31. Kurre, P., Morris, J., Horn, P.A., et al. Gene transfer into baboon repopulating cells: a comparison of Flt-3 ligand and megakaryocyte growth and development factor versus IL-3 during ex vivo transduction. Mol Ther 3:6 (2001), 920–927.
32. Wu, T., Kim, H.J., Sellers, S.E., et al. Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther 1:3 (2000), 285–293.
33. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:5466 (2000), 669–672.
34. Hacein-Bey-Abina, S., Hauer, J., Lim, A., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363:4 (2010), 355–364.
35. Gaspar, H.B., Parsley, K.L., Howe, S., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364:9452 (2004), 2181–2187.
36. Aiuti, A., Slavin, S., Aker, M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:5577 (2002), 2410–2413.
37. Cicalese, M.P., Ferrua, F., Castagnaro, L., et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood 128:1 (2016), 45–54.
38. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med, 3(97), 2011, 97ra80.
39. Candotti, F., Shaw, K.L., Muul, L., et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120:18 (2012), 3635–3646.
40. Shaw, K.L., Garabedian, E., Mishra, S., et al. A phase II clinical trial of gene therapy for adenosine deaminase-deficient severe combined immune deficiency using a gamma-retroviral vector and reduced intensity conditioning. J Clin Invest 120 (2017), 3635–3646.
41. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:5644 (2003), 415–419.
42. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16:2 (2010), 198–204.
43. Braun, C.J., Boztug, K., Paruzynski, A., et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med, 6(227), 2014, 227ra33.
44. Zufferey, R., Dull, T., Mandel, R.J., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:12 (1998), 9873–9880.
45. May, C., Rivella, S., Callegari, J., et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406:6791 (2000), 82–86.
46. Charrier, S., Stockholm, D., Seye, K., et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 12:7 (2005), 597–606.
47. Santilli, G., Almarza, E., Brendel, C., et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 19:1 (2011), 122–132.
48. Case, S.S., Price, M.A., Jordan, C.T., et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A 96:6 (1999), 2988–2993.
49. Mazurier, F., Gan, O.I., McKenzie, J.L., et al. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 103:2 (2004), 545–552.
50. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:5954 (2009), 818–823.
51. Biffi, A., Montini, E., Lorioli, L., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341(6148), 2013, 1233158.
52. Aiuti, A., Biasco, L., Scaramuzza, S., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341(6148), 2013, 1233151.
53. Hacein-Bey Abina, S., Gaspar, H.B., Blondeau, J., et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA 313:15 (2015), 50–63.
54. Gaspar, H.B., Buckland, K., Carbonaro, D.A., et al. Immunological and metabolic correction after lentiviral vector gene therapy for ADA deficiency. Mol Ther, 23(Suppl 1), 2015, S102.
55. De Ravin, S.S., Wu, X., Moir, S., et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med, 8(335), 2016, 335ra57.
56. Grosveld, F., van Assendelft, G.B., Greaves, D.R., et al. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell 51:6 (1987), 975–985.
57. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467:7313 (2010), 318–322.
58. Roselli, E.A., Mezzadra, R., Frittoli, M.C., et al. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med 2:8 (2010), 315–328.
59. Urbinati, F., Hargrove, P.W., Geiger, S., et al. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol 43:5 (2015), 346–351.
60. Baldwin, K., Urbinati, F., Romero, Z., et al. Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy. Stem Cells 33:5 (2015), 1532–1542.
61. Biasco, L., Pellin, D., Scala, S., et al. In vivo tracking of human hematopoiesis reveals patterns of clonal dynamics during early and steady-state reconstitution phases. Cell Stem Cell 19:1 (2016), 107–119.
62. Goncz, K.K., Prokopishyn, N.L., Chow, B.L., et al. Application of SFHR to gene therapy of monogenic disorders. Gene Ther 9 (2002), 691–694.
63. Porteus, M.H., Baltimore, D., Gene targeting in human cells. Science, 300(May), 2003, 75390.
64. Li, L., Krymskaya, L., Wang, J., et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21:6 (2013), 1259–1269.
65. Canver, M.C., Smith, E.C., Sher, F., et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527:7577 (2015), 192–197.
66. Dever, D.P., Bak, R.O., Reinisch, A., et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 539:7629 (2016), 384–389.
67. Wang, J., Exline, C.M., DeClercq, J.J., et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 33:12 (2015), 1256–1263.
68. Hoban, M.D., Lumaquin, D., Kuo, C.Y., et al. CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol Ther 24:9 (2016), 1561–1569.
69. DeWitt, M.A., Magis, W., Bray, N.L., et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med, 8(360), 2016, 360ra134.
70. De Ravin, S.S., Li, L., Wu, X., et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med, 9(372), 2017 [pii:eaah3480].
71. Komor, A.C., Kim, Y.B., Packer, M.S., et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533:7603 (2016), 420–424.
72. Boitano, A.E., Wang, J., Romeo, R., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:5997 (2010), 1345–1348.
73. Fares, I., Chagraoui, J., Gareau, Y., et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 345:6203 (2014), 1509–1512.
74. Dravid, G.G., Crooks, G.M., The challenges and promises of blood engineered from human pluripotent stem cells. Adv Drug Deliv Rev 63:4–5 (2011), 331–341.
75. Daniel, M.G., Pereira, C.F., Lemischka, I.R., et al. Making a hematopoietic stem cell. Trends Cell Biol 26:3 (2016), 202–214.
76. Petrillo, C., Cesana, D., Piras, F., et al. Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells. Mol Ther 23:2 (2015), 352–362.
77. Wang, C.X., Sather, B.D., Wang, X., et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 124:6 (2014), 913–923.
78. Santoni de Sio, F.R., Cascio, P., Zingale, A., et al. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107:11 (2006), 4257–4265.
79. Lisowski, L., Sadelain, M., Current status of globin gene therapy for the treatment of beta-thalassaemia. Br J Haematol 141:3 (2008), 335–345.
80. Czechowicz, A., Kraft, D., Weissman, I.L., et al. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318:5854 (2007), 1296–1299.
81. Chhabra, A., Ring, A.M., Weiskopf, K., et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med, 8(351), 2016, 351ra105.
82. Palchaudhuri, R., Saez, B., Hoggatt, J., et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol 34:7 (2016), 738–745.